Edition:
United States

Baxter International Inc (BAX)

BAX on New York Consolidated

62.60USD
26 Sep 2017
Change (% chg)

$-0.17 (-0.26%)
Prev Close
$62.76
Open
$62.86
Day's High
$62.88
Day's Low
$62.56
Volume
238,232
Avg. Vol
2,545,752
52-wk High
$64.75
52-wk Low
$43.13

Latest Key Developments (Source: Significant Developments)

Third Point Llc reports a stake of 7.5 pct in Baxter International
Friday, 2 Jun 2017 05:16pm EDT 

June 2 (Reuters) - Baxter International Inc :Third Point Llc reports a stake of 7.5 percent in Baxter International as of June 1 .Third Point Llc previously reported a stake of 8.5 percent in Baxter International as of Feb 28 .  Full Article

Baxter CEO José Almeida's FY 2016 compensation $5.8 mln vs $7.95 mln in FY 2015
Friday, 17 Mar 2017 05:04pm EDT 

Baxter International Inc :Ceo josé almeida's fy 2016 total compensation $5.8 million versus $7.95 million in fy 2015 - sec filing.  Full Article

Baxter Q3 adj earnings per share $0.56 from continuing operations excluding items
Tuesday, 25 Oct 2016 07:00am EDT 

Baxter International Inc : Baxter reports third quarter 2016 results and increases financial outlook for full-year 2016 . Sees Q4 2016 earnings per share $0.49 to $0.52 from continuing operations excluding items . Q3 GAAP earnings per share $0.23 from continuing operations . Q3 sales $2.6 billion versus i/b/e/s view $2.55 billion . Q3 earnings per share view $0.45 -- Thomson Reuters I/B/E/S . Raises FY 2016 earnings per share view to $1.88 to $1.91 from continuing operations excluding items . Q3 adjusted earnings per share $0.56 from continuing operations excluding items . Sees Q4 sales up about 2 percent . Baxter international inc - raising its financial outlook for full-year 2016 including sales growth of approximately 2 percent on a reported basis . Fy2016 earnings per share view $1.72, revenue view $10.15 billion -- Thomson Reuters I/B/E/S . Sees earnings from continuing operations, before special items, of $1.88 to $1.91 per diluted share for full year . Fy2016 earnings per share view $1.72 -- Thomson Reuters I/B/E/S . Baxter International Inc - on an adjusted basis Baxter's Q3 income from continuing operations totaled $0.56 per diluted share .Baxter International Inc - for Q4, company expects sales growth of approximately 2 percent on both a reported and constant currency basis.  Full Article

Sunshine Heart buys Baxter's Aquadex product line
Monday, 8 Aug 2016 05:30am EDT 

Sunshine Heart Inc: Sunshine Heart announces strategic acquisition of Aquadex product line from Baxter and a new credit facility with Silicon Valley Bank . Under terms of agreement, Baxter received $4.0 million in cash and 1.0 million shares of Sunshine Heart common stock . Entered into a new $5.0 million facility to finance future working capital needs . Company repaid all amounts outstanding under its existing debt facility with Silicon Valley Bank ."Expect product line to be accretive in first year".  Full Article

Baxter Q2 earnings $2.19/shr from cont ops
Tuesday, 26 Jul 2016 07:00am EDT 

Baxter Reports Second Quarter 2016 Results And Raises Financial Outlook For Full : Baxter reports second quarter 2016 results and raises financial outlook for full-year 2016 . For full-year 2016, baxter now expects sales growth of 3 percent to 4 percent on a constant currency basis . Year 2016 . Sees fy 2016 earnings per share $1.69 to $1.74 from continuing operations excluding items . Sees q3 2016 earnings per share $0.43 to $0.45 from continuing operations excluding items . Q2 gaap earnings per share $2.19 from continuing operations . Q2 sales $2.6 billion versus i/b/e/s view $2.52 billion . Q2 adjusted earnings per share $0.46 from continuing operations excluding items . Q2 earnings per share view $0.40 -- Thomson Reuters I/B/E/S . For full-year 2016, baxter now expects reported sales growth of 1 percent to 2 percent . Fy2016 earnings per share view $1.64, revenue view $10.09 billion -- Thomson Reuters I/B/E/S .Q3 earnings per share view $0.42, revenue view $2.53 billion -- Thomson Reuters I/B/E/S.  Full Article

EU Medicines Agency recommends approval of two new cancer drugs
Friday, 22 Jul 2016 07:21am EDT 

EU Medicines Agency : EU medicines agency recommendations for july 2016 . Recommends approval of Exelixis Inc’S cabozantinib to treat advanced renal cell carcinoma .Recommends Approval Of Baxter International Inc’S Irinotecan to treat pancreatic cancer.  Full Article

Baxter International sets quarterly dividend of $0.13 per share
Tuesday, 19 Jul 2016 09:00am EDT 

Baxter International Inc :Sets quarterly dividend of $0.13 per share.  Full Article

Baxter says Delaware court validates amendment to declassify company's board
Thursday, 23 Jun 2016 05:21pm EDT 

Baxter International Inc : Court of Chancery of State of Delaware validated charter amendment to declassify company's board of directors .Charter amendment will become effective on august 1, 2016.  Full Article

Baxter expects to generate free cash flow of about $1.75 bln in 2020
Monday, 9 May 2016 04:05pm EDT 

Baxter International Inc : Company provides financial outlook for 2018 and 2020 . Expects to grow sales 3 to 4 percent on a compounded annual basis at constant currency rates from 2016 through 2018 . Expects a 2018 adjusted operating margin of 14 to 15 percent and 2018 adjusted diluted earnings of $2.10 to $2.25 per share . Also expects free cash flow (operating cash flow less capital expenditures) of approximately $1.0 billion in 2018 . Expects sales to grow approximately 4 percent on a compounded annual basis at constant currency rates from 2016 to 2020 . Anticipates an adjusted operating margin of 17 to 18 percent and adjusted diluted earnings of $2.75 to $3.00 per share in 2020 .Expects to generate free cash flow of approximately $1.75 billion in 2020.  Full Article

Baxter International Inc raises quarterly dividend
Tuesday, 3 May 2016 08:30am EDT 

Baxter International Inc:Board of Directors has declared a 13 percent increase in the company's quarterly dividend rate, from the previous rate of $0.115 per Baxter common share to $0.13 per share.Dividend is payable on July 1, 2016 to stockholders of record as of June 3, 2016.  Full Article

BRIEF-Baxter International ‍announces commercial launch of new indication for oXiris set​

* Baxter launches first 3-in-1 set for use in continuous renal replacement therapy and sepsis management protocols